Author

Takuya Owari

National Cancer Center Exploratory Oncology Research & Clinical Trial Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Assay:multiome· 1

Frequent Co-Authors

Adam Stuart KibeliD· 1 shared Akihide YoshimiiD· 1 shared Asuka KawachiiD· 1 shared Atsuya Ishida· 1 shared Filipe L. De Carvalho· 1 shared Haruhito AzumaiD· 1 shared Hiroyoshi NishikawaiD· 1 shared Jia LiiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adam Stuart KibelORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

NECTIN4 defines a subtype-dependent tumor state coupling enfortumab vedotin targetability to antitumor immunity in bladder cancer

Kazuki Nishimura, Ryoichi Maenosono, Takuya Owari, Moritoshi Sakamoto, T Nishino, Kensuke Hirosuna, Takuya Tsujino, Takuya Izumi, Yuki Yoshikawa, Miyu Azuma, Sakura Inoue, Asuka Kawachi, Atsuya Ishida, Kei Nishimori, Junko Mukohyama, , Akihide Yoshimi

The paper identifies NECTIN4 as a subtype-dependent determinant of tumor state and antitumor immunity in bladder cancer, linking its expression to response to enfortumab vedotin and checkpoint inhibitors.

bioRxiv · Oct 9, 2026 · PreprintCancer Biology